S'abonner

Molecular pathways involved in COVID-19 and potential pathway-based therapeutic targets - 12/12/21

Doi : 10.1016/j.biopha.2021.112420 
Masoumeh Farahani a, 1, Zahra Niknam a, 1, Leila Mohammadi Amirabad b, Nasrin Amiri-Dashatan a, c, Mehdi Koushki d, Mohadeseh Nemati e, Fahima Danesh Pouya e, Mostafa Rezaei-Tavirani f, , Yousef Rasmi e, g, , Lobat Tayebi b
a Proteomics Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran 
b Marquette University School of Dentistry, Milwaukee, WI 53233, USA 
c Zanjan Metabolic Diseases Research Center, Zanjan University of Medical Sciences, Zanjan, Iran 
d Department of Clinical Biochemistry, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran 
e Department of Biochemistry, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran 
f Proteomics Research Center, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran 
g Cellular and Molecular Research Center, Urmia University of Medical Sciences, Urmia, Iran 

Correspondence to: Proteomics Research Center, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran 19716-53313, Iran.Proteomics Research Center, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical SciencesTehran19716-53313Iran⁎⁎Corresponding author at: Cellular and Molecular Research Center, Urmia University of Medical Sciences, Urmia, Iran.Cellular and Molecular Research Center, Urmia University of Medical SciencesUrmiaIran.

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Abstract

Deciphering the molecular downstream consequences of severe acute respiratory syndrome coronavirus (SARS-CoV)− 2 infection is important for a greater understanding of the disease and treatment planning. Furthermore, greater understanding of the underlying mechanisms of diagnostic and therapeutic strategies can help in the development of vaccines and drugs against COVID-19. At present, the molecular mechanisms of SARS-CoV-2 in the host cells are not sufficiently comprehended. Some of the mechanisms are proposed considering the existing similarities between SARS-CoV-2 and the other members of the β-CoVs, and others are explained based on studies advanced in the structure and function of SARS-CoV-2. In this review, we endeavored to map the possible mechanisms of the host response following SARS-CoV-2 infection and surveyed current research conducted by in vitro, in vivo and human observations, as well as existing suggestions. We addressed the specific signaling events that can cause cytokine storm and demonstrated three forms of cell death signaling following virus infection, including apoptosis, pyroptosis, and necroptosis. Given the elicited signaling pathways, we introduced possible pathway-based therapeutic targets; ADAM17 was especially highlighted as one of the most important elements of several signaling pathways involved in the immunopathogenesis of COVID-19. We also provided the possible drug candidates against these targets. Moreover, the cytokine-cytokine receptor interaction pathway was found as one of the important cross-talk pathways through a pathway-pathway interaction analysis for SARS-CoV-2 infection.

Le texte complet de cet article est disponible en PDF.

Graphical Abstract




ga1

Le texte complet de cet article est disponible en PDF.

Highlights

Potential molecular pathways involved in SARS-CoV-2 infection were investigated.
Pathway-based therapeutic targets were identified.
The importance of ADAM17 in several dysregulated molecular pathways was highlighted.
The predominant role of cytokine-cytokine receptor interaction pathway in cross-talk between pathways was indicated.

Le texte complet de cet article est disponible en PDF.

Abbreviations : COVID-19, SARS-CoV-2, ACE2, RAS, TNF-α, JNK, ERK, ACE, AT1R, PARP-1, PARG, TRPM2, TMPRSS2, ADAM17, ARDS, PAMP, PRRs, TLRs, NF-κB, JAK/STAT, mTOR, MAPKs, HIF-1, NLRP3

Keywords : COVID-19, SARS-CoV-2, Molecular pathway, Drug targets


Plan


© 2021  Publié par Elsevier Masson SAS.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 145

Article 112420- janvier 2022 Retour au numéro
Article précédent Article précédent
  • The molecular mechanisms of ferroptosis and its role in cardiovascular disease
  • Yang Zhang, Laiyun Xin, Mi Xiang, Chang Shang, Yuling Wang, Yan Wang, Xiangning Cui, Yingdong Lu
| Article suivant Article suivant
  • mTOR pathway: A potential therapeutic target for spinal cord injury
  • Yi Ding, Qin Chen

Bienvenue sur EM-consulte, la référence des professionnels de santé.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.